Exagamglogene Autotemcel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Exagamglogene Autotemcel Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
7
Registered trials
33
Result records
4
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Exagamglogene Autotemcel can convert its CRISPR/Cas9 profile and BCL11A biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Exagamglogene Autotemcel (query alias: exagamglogene) |
|---|---|
| Modality / target | CRISPR/Cas9; BCL11A; BCL11A inhibitors, Gene transference |
| Highest global status | Approved |
| Originator | CRISPR Therapeutics AG |
| Active developers | Vertex Pharmaceuticals, Inc., CRISPR Therapeutics AG, Vertex Pharmaceuticals (Europe) Ltd. (Ireland) |
The MCP disease footprint includes Beta-Thalassemia, Anemia, Sickle Cell, Transfusion-dependent Beta Thalassemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05477563 | Phase 3 | Recruiting | 26 | Fetal Hemoglobin (HbF) Concentration Over Time |
| NCT05356195 | Phase 3 | Active, not recruiting | 16 | Proportion of Participants who Achieve Transfusion Independence for at Least 12 Consecutive Months (TI12) |
| NCT05329649 | Phase 3 | Active, not recruiting | 13 | Proportion of Participants who do not Have any Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months (VF12) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
LONG-TERM FOLLOW-UP CONFIRMS DURABLE CLINICAL BENEFITS OF EXAGAMGLOGENE AUTOTEMCEL IN TRANSFUSION-DEPENDENT B-THALASSEMIA: FINAL RESULTS OF THE CLIMB THAL-111 STUDY
Phase 3; n=56; evaluation: Positive. Reported fields: TI12 = 98.2 %
DURABLE CLINICAL BENEFITS WITH EXAGAMGLOGENE AUTOTEMCEL FOR PEDIATRIC PATIENTS (5-11 YEARS) WITH TRANSFUSION-DEPENDENT Β‑THALASSEMIA AND SICKLE CELL DISEASE WITH RECURRENT VASO-OCCLUSIVE CRISES
Phase 3; n=24; evaluation: Positive. Reported fields: TI12 = 4.0 Participant ; TI12 = 6.0 Participant
DURABLE CLINICAL BENEFITS WITH EXAGAMGLOGENE AUTOTEMCEL FOR OVER 6 YEARS IN PATIENTS AGED 12 TO 35 YEARS WITH SICKLE CELL DISEASE WITH RECURRENT VASO-OCCLUSIVE CRISES
Phase 3; n=45; evaluation: Positive. Reported fields: death = There was one death which occurred 0.7 years after exa-cel infusion, which was previously reported, from respiratory failure due to COVID-19 infection not related to exa-cel
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Exagamglogene Autotemcel addresses Beta-Thalassemia, Anemia, Sickle Cell, Transfusion-dependent Beta Thalassemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—CRISPR/Cas9—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-12-18 | Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration | Approved | Financial terms not disclosed |
| 2022-09-28 | MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program | Phase 3 | Financial terms not disclosed |
| 2019-11-18 | Vertex teams up with Molecular Templates to globally explore and create specific conditioning regimens for hematopoietic stem cell transplants. | Phase 2 | US$38.0M upfront; US$522.0M milestones; US$560.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
